Full-Time

Director – Biostatistics

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$220k - $260kAnnually

+ Performance Bonus + Equity

Senior, Expert

Remote in USA

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
R
Requirements
  • PhD in statistics or biostatistics and 8+ years relevant experience in the pharmaceutical/biotechnology industry or MS in Biostatistics or Statistics and 11+ years relevant experience in the pharmaceutical/biotechnology industry
  • NDA submission experiences
  • Strong knowledge of statistical methodologies, current drug development trends, and regulatory environments.
  • Strong analytical and problem-solving skills; able to identify and investigate issues and causes independently and formulate potential solutions
  • Able to prioritize multiple tasks, develop instructions and manage vendors in completing the deliverables with high quality according to timelines, and provide recommendations to improve process
  • Excellent programming skills in SAS and/or R
  • Excellent oral and written communication skills
  • Ability to work as a part of a cross-functional team in a fast-paced environment and to work collaboratively with external partners and vendors
Responsibilities
  • Leads statistical and statistical programming team at the product level
  • Provides statistical input to strategic planning, study design, protocol development, sample size calculation, Case Report Form, Results Interpretation, clinical study report, and addressing questions from regulatory agencies. Develop and maintain SAPs, including the derived variables, the templates of statistical tables, figures, and listings
  • Provides guidance to study team on all aspects of statistical activities; collaborates closely with data manager to ensure high-quality data
  • Works collaboratively with Clinical Development, Clinical Operations, Clinical Data Managers, Pharmacovigilance & Epidemiology, Regulatory, Project Management, Translational Medicine, and other staff and vendors to meet project deliverables and timelines
  • CRO / Vendor Oversight: Establishes procedures through regular interaction, setting expectations on deliverables and timelines to guide CRO biostatisticians and statistical programmers. Ensures deliverables are accurate and delivered according to the timelines
  • Global Health Authority Interaction: Contributes to documents submitted to Health Authorities globally by providing input for the interaction or by writing the interaction document. May participate in meetings or teleconferences with Health Authorities
  • Coordinate with internal and external team members to prepare the statistical analyses for IB, DSUR updates, periodic safety updates, and other ad hoc safety analyses; participate in cross-functional study-related activities; attend team meetings

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

21%

1 year growth

53%

2 year growth

104%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with PANTHERx enhances patient access to rare disease therapies.
  • Recent investments indicate strong confidence in BridgeBio's business model.
  • Launch of BridgeBio Oncology Therapeutics accelerates targeted cancer therapy development.

What critics are saying

  • Alnylam's Amvuttra may challenge BridgeBio's Attruby in the market.
  • KRAS inhibitors face scientific challenges due to historical undruggability.
  • Decentralized model may lead to coordination challenges across drug programs.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for rapid drug development.
  • Focus on genetic diseases with well-understood causes sets BridgeBio apart.
  • BridgeBio leverages genome sequencing and molecular biology for targeted therapies.

Help us improve and share your feedback! Did you find this helpful?